Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q3 2025
Top Holdings32 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 5.1M | $1B | 13.1% | $129.52 | +47.93% | 18 qtrssince 2021-Q2 | Increased 65 |
UNITED THERAPEUTICS CORP | 2M | $847.7M | 11.0% | $151.50 | +180.07% | 20 qtrssince 2020-Q4 | Decreased 0 |
MADRIGAL PHARMACEUTICALS INC | 1.8M | $840.7M | 10.9% | $157.20 | +181.88% | 27 qtrssince 2019-Q1 | Decreased 0 |
ARGENX SE - ADR | 990,000 | $730.2M | 9.4% | $224.78 | +219.89% | 27 qtrssince 2019-Q1 | Decreased 0 |
Krystal Biotech, Inc. | 2.8M | $490.4M | 6.3% | $99.23 | +78.13% | 16 qtrssince 2021-Q4 | Increased 65 |
ARROWHEAD PHARMACEUTICALS IN | 10.9M | $375.9M | 4.9% | $27.02 | +25.02% | 10 qtrssince 2023-Q2 | Increased 60 |
KYMERA THERAPEUTICS INC | 6.4M | $359.4M | 4.6% | $32.85 | +78.10% | 17 qtrssince 2021-Q3 | Decreased 0 |
MERUS N V | 3.5M | $333.5M | 4.3% | $46.88 | — | 9 qtrssince 2023-Q3 | Increased 65 |
| 7.6M | $333.1M | 4.3% | $28.19 | +51.21% | 22 qtrssince 2020-Q2 | Increased 63 | |
APELLIS PHARMACEUTICALS INC | 12.2M | $276.6M | 3.6% | $42.79 | -47.07% | 19 qtrssince 2021-Q1 | Unchanged 0 |
CENTESSA PHARMACEUTICALS PLC | 10.8M | $262.1M | 3.4% | $19.73 | +23.65% | 3 qtrssince 2025-Q1 | Increased 92 |
uniQure N.V. | 4.4M | $259.4M | 3.4% | $23.90 | +148.53% | 4 qtrssince 2024-Q4 | Increased 69 |
XENON PHARMACEUTICALS INC | 5.4M | $216.8M | 2.8% | $21.38 | +82.66% | 27 qtrssince 2019-Q1 | Unchanged 0 |
AKERO THERAPEUTICS INC | 4M | $187.8M | 2.4% | $55.20 | — | 2 qtrssince 2025-Q2 | Increased 60 |
VERA THERAPEUTICS INC | 6.2M | $180.5M | 2.3% | $40.72 | -29.02% | 7 qtrssince 2024-Q1 | Decreased 0 |
SOLENO THERAPEUTICS INC | 2.6M | $174.3M | 2.3% | $47.52 | +43.44% | 8 qtrssince 2023-Q4 | Increased 65 |
STRUCTURE THERAPEUTICS INC | 5.2M | $144.4M | 1.9% | $25.30 | 0.00% | 1 qtr | New 70 |
TOURMALINE BIO INC | 2.6M | $122.2M | 1.6% | — | — | 8 qtrssince 2023-Q4 | Unchanged 0 |
OCULAR THERAPEUTIX INC | 10.3M | $119.8M | 1.5% | $9.87 | +26.96% | 7 qtrssince 2024-Q1 | Increased 63 |
AMICUS THERAPEUTICS INC | 15M | $118.4M | 1.5% | $11.07 | — | 27 qtrssince 2019-Q1 | Decreased 0 |
Avoro Capital Advisors LLC manages $7.7B across 32 positions as of Q3 2025. Top holdings: ASND (13.1%), UTHR (11.0%), MDGL (10.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.
Added 3 new positions, exited 3, increased 11, trimmed 11. Top move: CNTA (INCREASED, conviction 92). Portfolio: $7.7B across 32 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer